Daré Bioscience Q1 2025: Cash $10.3M, R&D down 31%, expects first revenue in Q4 2025

Dare Bioscience, Inc.

2025-Q1 EPS reported -$0.50 revenue$25,427

Cash and equivalents $10.3M at March 31, 2025; working capital deficit of $9.4M.
R&D expenses fell 31% YoY to $2.3M; G&A expenses decreased to $2.3M from $2.7M.
Targeting first revenue in Q4 2025 via Sildenafil Cream as 503B compounded drug; DARE-HRT1 in 2026.
Ovaprene Phase 3 contraceptive efficacy study ongoing; interim DSMB review scheduled for July 2025.
Strategy shift: dual path of 503B compounding and FDA approval; aiming for four on-market products by 2026.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.